Skip To Main Content
Chadi Hage Chehade on Muck Rack

Chadi Hage Chehade

As seen in: Wiley Online Library, MDPI, JAMA (The Journal of the American Medical Association), JAMA Network, Cell Press, Texas Medical Center, UroToday
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chadi Hage

Contact Chadi Hage, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States

|
By Chadi Hage Chehade
| JAMA Network Verified
Supplement 1. eTable 1. Univariable Cause-Specific Weibull AFT Model in Different Cancer Types by Advanced or Metastatic Diagnosis Year, Socioeconomic Status, Race-Ethnicity, Insurance Status, and Sex eTable 2. Subgroup Analysis of Prostate Cancer Stratified by Insurance Type eTable 3. Subgroup Analysis of Prostate Cancer Stratified by Socioeconomic Status eTable 4. Subgroup Analysis of Non–Small Cell Lung Cancer Stratified by Insurance Type eTable 5.
Open in Who Shared Issue with article?

Delayed Genomic Testing Limits Access to Life-Prolonging Cancer Treatments - Chadi Hage Chehade

|
By Chadi Hage Chehade
| UroToday Verified
Read the Full Video Transcript Neeraj Agarwal: Hi. My name is Dr. Neeraj Agarwal. I'm a professor of Medicine and director of Genitourinary Oncology Program at the Huntsman Cancer Institute, University of Utah. Today, I'd like to welcome Dr. Chadi Chehade, who is also from Huntsman Cancer Institute, to talk about his data he is presenting in an oral presentation at the ASCO 2025 meeting. So, Chadi, first of all, congratulations.
Open in Who Shared Issue with article?

Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma

|
By Zeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, Chadi Hage Chehade
| JAMA (The Journal of the American Medical Association) Verified
Key Points Question What are current treatment patterns and attrition rates in metastatic clear cell renal cell carcinoma (ccRCC)? Findings In this cohort study of 8534 patients with metastatic ccRCC, the most common first-line therapy before the approval of immune-checkpoint inhibitor (ICI)-based combinations was tyrosine kinase inhibitor monotherapy (78.8%); following their approval, ICI-based combinations were the most common first-line therapy (60.2%).
Open in Who Shared Issue with article?
See all 11 articles